Skip to content

Cancer Health Center

Font Size

Ewing Sarcoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information

continued...

The median age of patients with Ewing sarcoma is 15 years, and more than 50% of patients are adolescents. Well-characterized cases of Ewing sarcoma in neonates and infants have been described.[11,12] Based on data from 1,426 patients entered on European Intergroup Cooperative Ewing Sarcoma Studies (EI-CESS), 59% of patients are male and 41% are female. Primary sites of bone disease include the following:

  • Lower extremity (41%).
  • Pelvis (26%).
  • Chest wall (16%).
  • Upper extremity (9%).
  • Spine (6%).
  • Skull (2%).[13]

For extraosseous primary tumors, the most common primary sites of disease include the following:

  • Trunk (32%).
  • Extremity (26%).
  • Head and neck (18%).
  • Retroperitoneum (16%).
  • Other sites (9%).[13]

Approximately 25% of patients will have metastatic disease at diagnosis.[9]

The U.S. NCI SEER database was used to compare patients younger than 40 years with Ewing sarcoma who presented with skeletal and extraosseous primary sites.[14] Patients with extraosseous Ewing sarcoma were more likely to be older, female, nonwhite, and have axial primary sites and were less likely to have pelvic primary sites when compared with patients with skeletal Ewing sarcoma.

Table 1. Characteristics of Children With Extraosseous Ewing Sarcoma and Skeletal Ewing Sarcoma

CharacteristicExtraosseous Ewing SarcomaSkeletal Ewing SarcomaP Value
Mean age (range), years20 (0-39)16 (0-39)<.001
Male gender53%63%<.001
White (nonwhite race)85% (15%)93% (8%)<.001
Axial primary sites (non-axial primary)73% (27%)54% (46%)<.001
Pelvic primary sites (nonpelvic primary)20% (80%)27% (73%).001

Prognostic Factors for Ewing Sarcoma

The two major types of prognostic factors for patients with Ewing sarcoma are as follows:

  • Pretreatment.
  • Treatment response.

Pretreatment factors

  • Site of tumor: Patients with Ewing sarcoma in the distal extremities have the best prognosis. Patients with Ewing sarcoma in the proximal extremities have an intermediate prognosis, followed by patients with central or pelvic sites.[15,16,17] Patients with tumors of the sacrum have a very poor prognosis.[18]
  • Tumor size or volume: Tumor size or volume has been shown to be an important prognostic factor in most studies. Cutoffs of a volume of 100 mL or 200 mL and/or single dimension greater than 8 cm are used to define larger tumors. Larger tumors tend to occur in unfavorable sites.[17,19]
  • Age: Infants and younger patients (aged <15 years) have a better prognosis than adolescents aged 15 years or older, young adults, or adults.[12,15,16,17] In North American studies, patients younger than 10 years have a better outcome than those aged 10 to 17 years at diagnosis (relative risk [RR], 1.4). Patients older than 18 years have an inferior outcome (RR, 2.5).[20] A retrospective review of two consecutive German trials for Ewing sarcoma identified 47 patients older than 40 years.[21] With adequate multimodal therapy, survival was comparable to the survival observed in adolescents treated on the same trials.
  • Gender: Girls with Ewing sarcoma have a better prognosis than boys.[10,16]
  • Serum lactate dehydrogenase (LDH): Increased serum LDH levels prior to treatment are associated with inferior prognosis. Increased LDH levels are also correlated with large primary tumors and metastatic disease.[16]
  • Metastases: Any metastatic disease defined by standard imaging techniques or bone marrow aspirate/biopsy by morphology is an adverse prognostic factor. The presence or absence of metastatic disease is the single most powerful predictor of outcome. Metastases at diagnosis are detected in about 25% of patients.[9] Patients with metastatic disease confined to lung have a better prognosis than patients with extrapulmonary metastatic sites.[15,17,22] The number of pulmonary lesions does not seem to correlate with outcome, but patients with unilateral lung involvement do better than patients with bilateral lung involvement.[23] Patients with metastasis to bone only seem to have a better outcome than patients with metastases to both bone and lung.[24] Based on an analysis from the SEER database, regional lymph node involvement in patients is associated with an inferior overall outcome when compared with patients without regional lymph node involvement.[25]
  • Standard cytogenetics: Complex karyotype (defined as the presence of 5 or more independent chromosome abnormalities at diagnosis) and modal chromosome numbers lower than 50 appear to have adverse prognostic significance.[26]
  • Detectable fusion transcripts in morphologically normal marrow: Reverse transcriptase polymerase chain reaction can be used to detect fusion transcripts in bone marrow. In a single retrospective study utilizing patients with normal marrow morphology and no other metastatic site, fusion transcript detection in marrow was associated with an increased risk of relapse.[27]
  • Other biological factors: Overexpression of the p53 protein, Ki67 expression, and loss of 16q may be adverse prognostic factors.[28,29,30] High expression of microsomal glutathione S-transferase, an enzyme associated with resistance to doxorubicin, is associated with inferior outcome for Ewing sarcoma.[31]
1|2|3

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

Colorectal cancer cells
A common one in both men and women.
Lung cancer xray
See it in pictures, plus read the facts.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Do you know the symptoms?
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article